ストックスクリーナーアプリを入手
297.50
1.01%
-3.03
アフターアワーズ：
297.50
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Ligand Pharmaceuticals Inc (LGND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ligand Pharmaceuticals Inc (LGND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ligand Pharmaceuticals Inc (LGND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TradingKey - TradingKey
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
LGND|Ligand Pharmaceuticals Inc|Price:300.530|Chg%:-1.620 - TradingKey
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Inc (LGND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals to report Q2 2026 results on August 6 - scanx.trade
Ligand Sets Aug. 6 Webcast for Second-Quarter Results - Stock Titan
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
BofA Securities Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $388 - Moomoo
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Citi Initiates Buy Rating on Ligand Pharmaceuticals (LGND) Follo - GuruFocus
LGND Reinstated by Citigroup -- Price Target Announced at $387 - GuruFocus
Ligand (LGND) Receives Buy Rating with $387 Target from Citi - GuruFocus
XOMA (XOMA) removes unsold securities after $200M shelf and merger - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Press Release: Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More Than 200 Biopharmaceutical Royalty Assets - Moomoo
Free float of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $335 - Moomoo
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC : BENCHMARK RAISES TARGET PRICE TO $335 FROM $275 - Bitget
Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings - Yahoo Finance
XOMA Royalty Corp (XOMA) holders tender shares in Ligand merger - Stock Titan
XOMA Royalty Corp (XOMA) investors cashed out at $39 per share in Ligand merger - Stock Titan
Benchmark raises Ligand Pharma stock price target to $335 on XOMA deal - Investing.com Canada
Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Ligand Pharma (LGND) - The Globe and Mail
RBC Capital raises Ligand Pharma stock price target on financing By Investing.com - Investing.com Canada
RBC Capital Adjusts Price Target on Ligand Pharmaceuticals to $340 From $262, Maintains Outperform Rating - marketscreener.com
XOMA Royalty Corp (XOMA) director equity converted to $39 cash plus CVRs - Stock Titan
US53220KAJ7 Bond Profile — Key Metrics - TradingView
Ligand Pharmaceuticals Acquires XOMA Royalty for $739M, Doubling Portfolio to 200+ Biopharma Royalty Assets - Minichart
Ligand Pharmaceuticals Closes $739 Million XOMA Royalty Purchase - marketscreener.com
Ligand Pharmaceuticals Amends and Extends $125 Million Revolver to 2028 With Citibank - TradingView
Ligand Pharmaceuticals (Nasdaq: LGND) closes $739M XOMA Royalty acquisition - Stock Titan
XOMA Royalty Announces Closing of Its Acquisition by Ligand - The Manila Times
Ligand completes acquisition of XOMA Royalty for $39 per share By Investing.com - Investing.com Canada
Ligand completes $739M acquisition of XOMA Royalty Corporation By Investing.com - Investing.com Canada
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets - marketscreener.com
Press Release: XOMA Royalty Announces Closing of Its Acquisition by Ligand - Moomoo
XOMA Royalty Corp (XOMA) legal chief’s stock and PSUs converted in Ligand merger - Stock Titan
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
3 Overlooked Stocks Positioned for the Next Market Rotation - Investing.com
Agenus Inc. announced that it expects to receive $85 million in funding from RA Capital Management, L.P., Ligand Pharmaceuticals Incorporated - marketscreener.com
BofA raises Ligand Pharma stock price target on royalty growth By Investing.com - Investing.com South Africa
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Price to book forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView
Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $299.22, Implies 5% Downside - TradingView
LGND Maintained by B of A Securities -- Price Target Raised to $388 - GuruFocus
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):